a cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart diseasecardiologic方法未抗糖尿病的胰岛素患者的药物治疗心脏病.pdfVIP

下载本文档

0
0
约10.91万字
约 13页
2017-09-10 发布于上海
举报
版权申诉

a cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart diseasecardiologic方法未抗糖尿病的胰岛素患者的药物治疗心脏病.pdf

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

a cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart diseasecardiologic方法未抗糖尿病的胰岛素患者的药物治疗心脏病

Cardiovascular Diabetology BioMed Central Review Open Access A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease Enrique Z Fisman*1,2 and Alexander Tenenbaum1,2,3 Address: 1Sackler Faculty of Medicine, Tel-Aviv University, 69978 Ramat-Aviv, Tel-Aviv, Israel, 2Cardiovascular Diabetology Research Foundation, 58484 Holon, Israel and 3Cardiac Rehabilitation Institute, Sheba Medical Center, 52621 Tel-Hashomer, Israel Email: Enrique Z Fisman* - zfisman@post.tau.ac.il; Alexander Tenenbaum - altenen@post.tau.ac.il * Corresponding author Published: 20 July 2009 Received: 14 July 2009 Accepted: 20 July 2009 Cardiovascular Diabetology 2009, 8:38 doi:10.1186/1475-2840-8-38 This article is available from: /content/8/1/38 © 2009 Fisman and Tenenbaum; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Classical non-insulin antihyperglycemic drugs currently approved for the treatment of type 2 diabetes mellitus (T2DM) comprise five groups: biguanides, sulfonylureas, meglitinides, glitazones and alpha- glucosidase inhibitors. Novel compounds are represented by the incretin mimetic drugs like glucagon like peptide-1 (GLP-1), the dipeptidyl peptidase 4 (DPP-4) inhibitors, dual peroxisome proliferator-activated receptors (PPAR) agoni